Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Apatinib in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma After Failure of Two or More Lines of Chemotherapy (Ahead-G201): a Prospective, Single-arm, Multicenter, Phase IV Study

NCT02426034 is registered in ClinicalTrials.gov with Jiangsu HengRui Medicine Co., Ltd. as lead sponsor.

NCT NCT02426034
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02426034 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Apatinib in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma After Failure of Two or More Lines of Chemotherapy (Ahead-G201): a Prospective, Single-arm, Multicenter, Phase IV Study
Lead sponsor
Jiangsu HengRui Medicine Co., Ltd.
Phase
Phase 4
Overall status
Completed
Start date
May 15, 2015
Completion date
September 3, 2020
Enrollment
2,004 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastric or gastroesophageal junction adenocarcinoma